S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CMMB

Chemomab Therapeutics (CMMB) Stock Price, News & Analysis

$0.78
+0.01 (+1.30%)
(As of 03/28/2024 ET)
Today's Range
$0.75
$0.78
50-Day Range
$0.50
$0.86
52-Week Range
$0.42
$1.89
Volume
28,961 shs
Average Volume
241,012 shs
Market Capitalization
$8.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Chemomab Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
798.6% Upside
$7.00 Price Target
Short Interest
Healthy
1.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Chemomab Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.20) to ($1.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.19 out of 5 stars

CMMB stock logo

About Chemomab Therapeutics Stock (NASDAQ:CMMB)

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

CMMB Stock Price History

CMMB Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
US Stocks Gain; Producer Prices Fall In October
Chemomab Reports Fast Track Designation For CM-101 - Quick Facts
Chemomab Therapeutics GAAP EPS of $0.017
See More Headlines
Receive CMMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CMMB
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+798.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-24,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.54 per share

Miscellaneous

Free Float
9,734,000
Market Cap
$8.61 million
Optionable
Not Optionable
Beta
0.34
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Adi Mor George Ph.D. (Age 42)
    Co-Founder, Chief Scientific Officer, CEO & Executive Director
    Comp: $435.4k
  • Ms. Sigal Fattal CPA (Age 53)
    M.B.A., Chief Financial Officer
    Comp: $258k
  • Barbara Lindheim
    Consulting Vice President of Investor & Public Relations, Strategic Communications
  • Dr. Matthew B. Frankel M.B.A. (Age 54)
    M.D., Chief Medical Officer & VP of Drug Development

CMMB Stock Analysis - Frequently Asked Questions

Should I buy or sell Chemomab Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CMMB shares.
View CMMB analyst ratings
or view top-rated stocks.

What is Chemomab Therapeutics' stock price target for 2024?

3 Wall Street research analysts have issued twelve-month price objectives for Chemomab Therapeutics' stock. Their CMMB share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 798.6% from the stock's current price.
View analysts price targets for CMMB
or view top-rated stocks among Wall Street analysts.

How have CMMB shares performed in 2024?

Chemomab Therapeutics' stock was trading at $0.51 at the beginning of the year. Since then, CMMB stock has increased by 52.7% and is now trading at $0.7790.
View the best growth stocks for 2024 here
.

Are investors shorting Chemomab Therapeutics?

Chemomab Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 194,200 shares, a drop of 20.5% from the February 29th total of 244,300 shares. Based on an average trading volume of 235,800 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.8% of the shares of the company are short sold.
View Chemomab Therapeutics' Short Interest
.

When is Chemomab Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CMMB earnings forecast
.

How were Chemomab Therapeutics' earnings last quarter?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) posted its earnings results on Thursday, March, 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.14. During the same quarter in the prior year, the firm earned ($0.72) EPS.

How do I buy shares of Chemomab Therapeutics?

Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMMB) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners